跳至主要内容
临床试验/JPRN-UMIN000003487
JPRN-UMIN000003487已完成未知

Phase II study of cisplatin plus S-1 with bevacizumab as first-line therapy for stage III/IV nonsquamous non-small-cell lung cancer - Phase II study of CDDP+S-1+Bevacizumab for advanced nonsquamous non-small-cell lung cancer

Gunma University Hospital0 个研究点目标入组 24 人开始时间: 2010年4月16日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 75years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • squamous cell (adenosquamous cell) lung cancer; Patients with a history of serious drug allergy, hemoptysis, thrombosis, concomitant malignancy, central nervous system metastases, active infectious diseases or other serious medical problems;hemorrhagic diathesis or coagulopathy; therapeutic anticoagulation; regular use of aspirin (>325 mg per day), nonsteroidal antiinflammatory agents, or other agents known to inhibit platelet function;use of steroid or flucytosine;pregnancy ;

研究者

相似试验

Phase II study of cisplatin plus S-1 with... | 临床试验